Skip to content

Study · Observational study · n = 228 · 2019

4 results

Effects of teriparatide in Chinese and Caucasian women with osteoporosis: bridging study on efficacy.

Xie Z, Chen Y, Gurbuz S, Zhang B, Li Y, Bai F, Chen Y

Clinical interventions in aging27 May 2019Cited by 3 (Europe PMC)

PMID31213783 (opens in a new tab)PMCIDPMC6542327 (opens in a new tab)DOI10.2147/cia.s181929 (opens in a new tab)PepBankPUB-31213783
Read at sourcePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In Chinese women with osteoporosis, teriparatide increased lumbar spine BMD more than calcitonin, with a 5.0% least-squares mean difference.

    In plain wordsIn Chinese women with osteoporosis, teriparatide increased spine bone density more than calcitonin.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseLumbar spine BMD in Chinese study
    Study

    n = 228

    Comparator
    Calcitonin
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Measurements

    Least-squares mean difference in LS-BMD change
    5%
    teriparatide versus calcitonin, Chinese study

    Source sentences

    Summary
    For changes in LS-BMD from baseline to week 24, treatment with teriparatide showed significantly greater increases (P-values <0.001; least-squares mean difference: 5.0% in the Chinese study and 5.4% in FPT) than comparator (calcitonin/placebo).
    3 context sentences
    Summary · context
    To bridge the efficacy and compare the safety of the 24-week teriparatide treatment in a Chinese osteoporosis study (NCT00414973) to a large international trial (FPT, NCT00670501) to determine whether long-term results from the international study were applicable to Chinese patients.
    Summary · context
    In this post-hoc analysis, a propensity score matching method was used to select patients with similar baseline characteristics.
    Summary · context
    Patients were female with osteoporosis at high risk of fracture, aged ≥55 years, and had no history of rheumatoid arthritis or corticosteroid use.
  2. 02HumanObservational studyEfficacy outcome

    In matched FPT women with osteoporosis, teriparatide increased lumbar spine BMD more than placebo, with a 5.4% least-squares mean difference.

    In plain wordsIn matched FPT women with osteoporosis, teriparatide increased spine bone density more than placebo.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseLumbar spine BMD in FPT at week 24
    Study

    n = 228

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Measurements

    Least-squares mean difference in LS-BMD change
    5.4%
    teriparatide versus placebo, FPT week 24

    Source sentences

    Summary
    For changes in LS-BMD from baseline to week 24, treatment with teriparatide showed significantly greater increases (P-values <0.001; least-squares mean difference: 5.0% in the Chinese study and 5.4% in FPT) than comparator (calcitonin/placebo).
    2 context sentences
    Summary · context
    In this post-hoc analysis, a propensity score matching method was used to select patients with similar baseline characteristics.
    Summary · context
    Patients were female with osteoporosis at high risk of fracture, aged ≥55 years, and had no history of rheumatoid arthritis or corticosteroid use.
  3. 03HumanObservational studyEfficacy outcome

    In matched FPT women, teriparatide increased long-term lumbar spine BMD more than placebo, with an 11.5% least-squares mean difference.

    In plain wordsIn matched FPT women, teriparatide increased long-term spine bone density more than placebo.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseLong-term lumbar spine BMD
    Study

    n = 228

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Measurements

    Least-squares mean difference in long-term LS-BMD change
    11.5%
    teriparatide versus placebo, matched FPT patients

    Source sentences

    Summary
    For matched-pair FPT patients, long-term changes in LS-BMD were significantly greater (least-squares mean difference: 11.5%, PP=0.070).
    2 context sentences
    Summary · context
    In this post-hoc analysis, a propensity score matching method was used to select patients with similar baseline characteristics.
    Summary · context
    Patients were female with osteoporosis at high risk of fracture, aged ≥55 years, and had no history of rheumatoid arthritis or corticosteroid use.
  4. 04HumanObservational studyEfficacy outcome

    In matched FPT women, fragility fractures were marginally less frequent with teriparatide than placebo, without statistical significance.

    In plain wordsIn matched FPT women, fracture rates were lower with teriparatide than placebo, but the difference was not statistically significant.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeFragility fracture rate
    Study

    n = 228

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Measurements

    Fragility fracture rate
    13.1%
    teriparatide
    Fragility fracture rate
    22.3%
    placebo

    Source sentences

    Summary
    For matched-pair FPT patients, long-term changes in LS-BMD were significantly greater (least-squares mean difference: 11.5%, PP=0.070).
    2 context sentences
    Summary · context
    In this post-hoc analysis, a propensity score matching method was used to select patients with similar baseline characteristics.
    Summary · context
    Patients were female with osteoporosis at high risk of fracture, aged ≥55 years, and had no history of rheumatoid arthritis or corticosteroid use.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.